Are You A Good Candidate For Liposuction? Yily De Los Santos Plastic Surgeon Explains

MIAMI, FL, UNITED STATES, October 1, 2020 /EINPresswire.com/ — Liposuction can sound like an easy solution when you want to lose weight, but Dra. Yily De Los Santos, plastic surgeon, explains that that's not always the case. Dra. Yily De Los Santos explains who is a good candidate for liposuction, and how you can decide if the procedure is a good option for you.

Dra. Yily De Los Santos says that candidates for liposuction are within 30% of their ideal weight. If you're not sure what's a good ideal weight range for your age, height, and body type, Dra. Yily De Los Santos recommends talking to your doctor. If you're not currently within the proper weight range, your doctor can work with you to help you develop a plan that will get you where you need to be in order to consider liposuction.

Your skin is another important consideration when deciding if you're a good candidate for liposuction. According to Dra. Yily De Los Santos, good candidates for liposuction have elastic, firm skin. After your liposuction procedure, your skin will go through an adjustment period. Dra. Yily De Los Santos recommends talking with your plastic surgeon about what you can expect in terms of your skin recovery after your procedure. It may take some time for your skin to catch up with the progress your body makes during liposuction. During standard weight loss, your skin has plenty of time to slowly change as you lose fat. With liposuction, fat loss is immediate, and the skin can take some extra time to change shape.

Dra. Yily De Los Santos says that it's also important for you to have good muscle tone before beginning to consider liposuction. Liposuction is a cosmetic procedure, and you'll want to have the aesthetically pleasing results you imagine. In order for your body to have the strong, toned look you want, it's key that you have solid muscle tone. Dra. Yily De Los Santos recommends beginning an exercise program with the guidance of your doctor before you consider liposuction.

Dra. Yily De Los Santos states that it's also important that you're in general physical good health. While liposuction is an elective procedure, it still carries the same risks as any surgery. Dra. Yily De Los Santos recommends working to improve your physical health before considering an elective surgical procedure.

Of course, your doctor is the one to make the final call of whether you're in a good state of body and mind for liposuction. Dra. Yily De Los Santos recommends talking with your doctor about the steps you can take now to improve your health if you're considering liposuction in the future.

Caroline Hunter
Web Presence, LLC
+17862338220
email us here


Source: EIN Presswire

HACIA LA EXPANSIÓN 2021 DE CLIMACELL LATAM

La plataforma de inteligencia meteorológica más asertiva para los negocios

Con ClimaCell, nuestros equipos de operaciones saben qué esperar y cuándo para poder planificar con antelación. Estamos ahorrando millones de pesos al año utilizando esta plataforma”

— Pablo Aznavurian, Director de Operaciones de Vuelo de Aeroméxico

MEXICO, October 1, 2020 /EINPresswire.com/ — Ciudad de México, a 29 de septiembre de 2020.- Este ha sido un año retador para los negocios en todo el mundo por diversas razones, sin duda, la principal el COVID-19 aunado a fenómenos meteorológicos como incendios, tormentas tropicales e inundaciones que hacen evidente que el impacto del clima sobre las operaciones comerciales nunca había representado un reto tan importante. Para las empresas de la industria climática, el mercado está presentando una demanda de visiones empresariales predictivas y eficaces sin precedentes, ya que los pronósticos meteorológicos básicos han alcanzado su máximo valor para ayudar a los ejecutivos operativos a tomar decisiones financieras importantes con confianza. Aquí algunos insights interesantes:

● 70% de las empresas se ven impactadas por el clima
● El impacto climatológico y la volatilidad es mencionada en el top 5 de las principales preocupaciones de los CEOs
● La frustración #1 es que los datos meteorológicos no son lo suficientemente precisos para ser prácticos
● 85% el mundo no tiene datos meteorológicos confiables en tiempo real
● 90% de las empresas no entienden de qué forma aprovechar la información meteorológica a su favor

ClimaCell, la principal Plataforma de Inteligencia Meteorológica en el mundo, no sólo ha logrado un impacto considerable en una serie de industrias como: cadenas de suministro, energía, servicios on-demand, tecnología, y otros más, sino que también ha centrado sus esfuerzos de expansión y valor en todo el mundo, incluyendo áreas de interés estratégico como LATAM, todo esto es posible gracias a la alianza con LIP Ventures Boutique, quienes representan y comercializan la plataforma.

LIP Ventures Boutique (lip.lat), fundada por los mexicanos Mario Nissan y Nathan Shabot, tiene el firme propósito de acercar a México y Latinoamérica oportunidades de negocios en el mundo de la innovación. Se define como una “boutique de innovación” que busca agregar y generar valor para sus stakeholders al proveer servicios especializados y acceso a startups multiregionales de tecnología, al mismo tiempo que aceleran el “leapfrogging”, concepto que inspiró su marca LIP (Leapfrog Innovation Powerhouse), y que se refiere al avance constante, a pasos exponenciales, que permite a las empresas adentrarse en la revolución tecnológica. LIP Ventures Boutique tiene 3 verticales de negocios: Venture Capital, Open Innovation (innovación abierta) y Business Development (desarrollo de negocios).

Con las industrias de turismo, envíos, cadenas de suministro y energía tomando un papel de sectores protagónicos este año, ClimaCell ha demostrado ser particularmente valiosa para algunas de las principales empresas de esas industrias en LATAM, incluyendo Rappi, Aeroméxico, y muchas otras.

Con su enfoque principal sobre la industria de la Inteligencia Meteorológica y empoderando a los equipos a entender el impacto comercial y operativo del clima que está por venir, ClimaCell ha automatizado una industria la cual ha estado rodeada de confusión y error humano por más de 50 años.

“Con ClimaCell, nuestros equipos de operaciones saben qué esperar y cuándo para poder planificar con antelación. Estamos ahorrando millones de pesos al año utilizando esta plataforma en la optimización del personal, el uso de materiales y la planificación de recursos,” comentó Pablo Aznavurian, Director de Operaciones de Vuelo (SVP FO) de Aeroméxico. “La industria aérea se ha vuelto aún más volátil para nuestros equipos este año, pero una de las herramientas más reconfortantes que hemos tenido para superar el caos es ClimaCell y su increíble equipo”.

Otras industrias que aprovechan el software como servicio (SaaS) y la API de ClimaCell incluyen la de energía y servicios públicos, minería, ferrocarriles, camiones, carga aérea, entre otras. “Predecir el impacto operativo del pronóstico meteorológico es un desafío importante que enfrentan la mayoría de los países de LATAM debido a la falta de infraestructura y recursos de mantenimiento”, mencionó Shimon Elkabetz, Director General y cofundador de ClimaCell. “Cada avance progresivo representa un cambio radical para ahorrar dinero, mejorar la eficiencia y el rendimiento del tiempo; así mismo, salva vidas a través de operaciones más seguras. Nuestro equipo está trabajando en conjunto con líderes sectoriales de toda la región para proporcionar los conocimientos de automatización y de toma de decisiones que el mercado lleva requiriendo desde hace mucho tiempo y hasta ahora, y como empresa, estamos muy emocionados de las oportunidades regionales a medida que avanzamos.”

Para más información sobre Climacell, favor de ingresar a: https://www.climacell.co.
Para dudas comerciales y saber cómo ClimaCell puede ayudar a tu negocio envía un mail a LIP Ventures Boutique: climacell@lip.lat.

Acerca de ClimaCell
Con su plataforma de inteligencia meteorológica impulsada por IA, ClimaCell automatiza la toma de decisiones operativas y los planes de acción en función del impacto comercial histórico, en tiempo real y pronóstico del clima. Habiendo duplicado su plantilla de empleados en 2019 y logrando un crecimiento de ingresos 7 veces mayor, ClimaCell se encuentra en un camino de crecimiento agresivo hacia la revolución de la industria del clima con clientes como Uber, Delta, Ford, Intact Insurance, National Grid, el US Open, Rappi, Porsche, y más.

Lizette Weber
Lizette Weber PR Agency
+52 55 6628 5614
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Carolina Panthers: First NFL Team to Debut & Deploy Xenex LightStrike, World’s Only Proven Coronavirus-Killing UV Robot

Xenex LightStrike Robot Carolina Panthers' Locker Room

Xenex LightStrike Coronavirus-Killing Robot Zaps Carolina Panthers’ Locker Room (Source: Bryan Glazer | World Satellite Television News)

Xenex LightStrike Robot Carolina Panthers

Xenex LightStrike Coronavirus-Killing Robot Zaps Carolina Panthers’ Weight Room (Source: Bryan Glazer | World Satellite Television News)

Xenex LightStrike Robot Carolina Panthers

Xenex LightStrike Coronavirus-Killing Robot Set-Up in Carolina Panthers’ Locker Room (Source: Bryan Glazer | World Satellite Television News)

Bank of America Stadium Germ-Zapped by One-of-a-Kind Xenon UV-Ray Room Disinfecting Device: 99.99% Effective at Destroying SARS-CoV-2 | B-Roll & Photos Below

No other ultra-violet light room disinfection device is proven to destroy SARS-CoV-2.”

— Morris Miller, CEO, Xenex, Inc.

CHARLOTTE, NC, UNITED STATES, October 1, 2020 /EINPresswire.com/ — In the midst of the Covid-19 crisis; during the fourth week of the NFL season, the Carolina Panthers become America’s first professional football team to debut and deploy the World’s Only Proven Coronavirus-Killing Xenon UV-Ray Robot.

( Click: B-Roll & Bites | Photos )

The Xenex LightStrike Robot is the world’s most-powerful ultraviolet light ray, germ-zapping robot, according to more than 40 university and hospital studies.

LightStrike is now being utilized to disinfect an array of player and public areas at Bank of America Stadium in uptown Charlotte.

On Sunday, October 4, 2020, for the first-time since the football season started, a limited number of spectators will be permitted to attend the 1:00 p.m. (ET) game between the Panthers and Arizona Cardinals at Bank of America Stadium. The Cardinals locker room and equipment

Journal of Infection Control & Epidemiology

According to a peer-reviewed study published in the journal, "Infection Control and Hospital Epidemiology," researchers concluded that LightStrike is 99.99% effective at destroying SARS-CoV-2 — the virus that causes Covid-19.

No other ultraviolet light room disinfection device is proven to destroy SARS-CoV-2.

“There are a lot of companies making claims about their newly-introduced UV wands and other devices,” says Morris Miller, CEO of San Antonio, Texas-based Xenex, Inc. “We call that the theater of disinfection. The LightStrike robot is the only device that has been proven to kill SARS-CoV-2, that causes Covid-19, in two minutes.”

Those are the findings of tests conducted at the Texas Biomedical Research Institute, which is one of only 10 BioSafety Level Four Labs in North America, according to Miller.

“The significance of an NFL team, in this case, the Carolina Panthers, using a LightStrike robot, shows that they're making a concrete commitment to player safety,” says Miller. “They want to ensure that those locker rooms, showers, or any other shared areas are safe for the next player that enters, even if a previous player happened to have an infection.”

Panthers’ Robot Prowls Bank of America Stadium

Ed Levins, the Carolina Panthers' Director of Security and Infection Control Officer, explains, “Our goal, when we first-started working on the infectious disease response plan for this stadium, was to make sure that this was the safest possible stadium in the NFL.”

He continues, “What we found-out about the opportunities that existed with UV operations, was that the Xenex product was exactly what we were looking for; that it is the best thing for our players, so they could feel safe; that we were doing everything possible to make them feel comfortable coming back in here. We also want our fans to feel like this is the safest place and the cleanest place that they could come to enjoy a football game.”

LightStrike is used in 650 healthcare facilities and surgical centers around the globe. They include Rochester, Minnesota’s Mayo Clinic, The University of Texas MD Anderson Cancer Center in Houston and Veteran’s Affairs hospitals across America.

And, now, for the first-time, LightStrike is being used by a professional sports organization in its stadium, player facilities, public areas and offices.

Carolina Panthers’ LightStrike-trained technicians are currently germ-zapping parts of the Bank of America Stadium, on a daily basis. The areas being treated include locker rooms, meeting rooms, offices, rehabilitation areas, restrooms, suites, weight rooms and work-out areas.

October 4, 2020: Spectators Return to Disinfected Stadium

While most NFL games have been played in near-vacant stadiums, some teams are allowing spectators to trickle-in as the season progresses.

North Carolina Governor Roy Cooper announced that he will allow a capacity of seven-percent, starting Friday, Oct. 2, 2020, for large venues with a seating capacity of more than 10,000 people.

Based on that allowance, the Panthers would be able to have about 5,240 fans in attendance for their second home game of the season when they host the Arizona Cardinals.

The stadium seats 74,867 people and features 151 luxury suites.

The exact seating details have yet to be announced.

LightStrike Technology

LightStrike’s intense, pulsating bursts of Xenon UV light are not only proven to destroy SARS-CoV-2, the virus that causes Covid-19; but its robotic room disinfection system also quickly deactivates C.diff, Ebola, MRSA, SARS and other viruses and pathogens, according to an array of studies published by major universities and hospitals.

The robots’ broad-range spectrum of UV light wavelengths penetrate the cell walls of pathogens and destroys their molecular structure. This includes the deadly coronavirus.

Not for Use on Humans and Animals

LightStrike is not for use on humans and animals. It does, however, disinfect an array of surfaces including computers, countertops, doors, elevators, fitness equipment, floors, furniture, kitchens, lavatories and showers.

“People are looking for a disease conscious lifestyle,” explains Miller. “They want to make sure when they go into a public space, that they're not going to get sick because of pathogens that have been left on the environment.”

According to the CDC, coronavirus can remain active on surfaces for more than 14-days.

While most people equate the term, “robot,” to an autonomous-moving device, LightStrike is moved from one-location to the next by a trained technician.

Despite the “human element;” because LightStrke is equipped with a retractable Xenon-UV lamp, MassRobotics, an independent, non-profit center serving to educate and inspire the development of robotics, defines the Xenex room disinfection device as a, “robot.”

More About Xenex LightStrike

▪ Made-in-San Antonio, Texas.

▪ $125,000; equates to $100 daily over 37-month period.

▪ Hospitals report disinfecting 60+ rooms per day with single robot; $3 per room.

▪ Bursts of brilliant, broad spectrum UV light that quickly destroys microscopic viruses and bacteria that remain in room, even after cleaned with liquid disinfectants.

▪ Different pathogens susceptible to UV light at different wavelengths.

▪ With broad spectrum UV light, LightStrike robots quickly deactivate viruses and bacteria by destroying their molecular structures and cell walls.

More at Xenex.com

Bryan Glazer | World Satellite Television News | Bryan@Televisionews.com | 561.374.1365

Melinda Hart | Xenex Disinfection Services | Melinda.Hart@Xenex.com | 210.240.4669

Bryan Glazer
World Satellite Television News
+1 561-374-1365
email us here

2-Minute Sizzle Video Xenex-LightStrike-Debuted & Deployed By Carolina Panthers | Bryan Glazer World Satellite Television News


Source: EIN Presswire

The Global Protein Inhibitors Market Size Will Recover And Grow At 9.78% CAGR To 2023

Global Protein Inhibitors Market Size, 2019 – 2023, $ Billion

Global Protein Inhibitors Market, Forecast Market Size, 2019 – 2023, $ Billion

The Business Research Company’s Global Protein Inhibitors Market Report 2020-30: Covid 19 Growth And Change

LONDON, GREATER LONDON, UK, September 30, 2020 /EINPresswire.com/ — The global protein inhibitors market size is expected to decline from $59.66 billion in 2019 to $56.97 billion in 2020 at a compound annual growth rate (CAGR) of -4.5%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The global protein inhibitors market size is then expected to recover and reach $75.37 billion in 2023 at a CAGR of 9.78%.

The increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and autoimmune diseases is predicted to contribute to the protein inhibitors market growth. According to the World Health Organization, chronic diseases are expected to become the seventh leading cause of death globally, by the end of 2030.

According to the National Health Council’s report published in 2019, there were approximately 133 million Americans affected by chronic diseases, estimated to be 40% of the total population of the country. The number is expected to reach 157 million by 2020, with 87 million people having multiple conditions. Protein inhibitors are used for the treatment of these diseases due to fewer adverse effects and higher efficacy. Therefore, the increasing number of people with chronic diseases is anticipated to drive demand in the protein inhibitors market.

Companies in the protein inhibitors market are increasingly investing in various strategic initiatives such as partnerships and collaborations to develop new drugs to meet the market demand. Strategic collaborations and partnership agreements help companies to expand their existing product portfolio and geographical presence.

For instance, in February 2020, Catalent Inc., a US-based provider of delivery technologies, drug manufacturing, gene therapies, biologics, and consumer healthcare products, announced a partnership agreement with Zumutor Biologics Inc., an immune-oncology company based in the USA, to manufacture ZM008, a monoclonal antibody targeting solid tumors. Moreover, in July 2018, Anima Biotech, a US-based biotechnology company, announced a partnership agreement with Eli Lilly and Company, a US-based pharmaceutical company, for the development and discovery of translation inhibitors of several protein targets using Anima Biotech’s translation control therapeutics platform.

The protein inhibitors market share consists of sales of protein inhibitors by entities (organizations, sole traders, and partnerships) that are engaged in the manufacturing of protein inhibitors. Protein synthesis inhibitors stop the development of cells by disrupting the process leading to the generation of new proteins. Protein inhibitors is a pharmaceutical drug that acts on the proteins (special target) in the body and finds applications in the treatment of various diseases such as cancer, autoimmune diseases, infectious diseases, and others.

Here Is A List Of Similar Reports By The Business Research Company:
Protein Labeling Global Market Report 2020-30: COVID-19 Growth And Change (https://www.thebusinessresearchcompany.com/report/protein-labeling-global-market-report-2020-30-covid-19-growth-and-change)

Protein Expression Global Market Report 2020-30: Covid 19 Growth And Change (https://www.thebusinessresearchcompany.com/report/protein-expression-global-market-report)

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The World’s Most Comprehensive Database
The Business Research Company’s flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

The Development Of Innovative, Customized Vascular Grafts Is Gaining Traction In The Global Vascular Grafts Market 2020

Global Vascular Grafts Forecast Market Size, 2019 – 2023, $ Billion

Global Vascular Grafts Market, Forecast Market Size, 2019 – 2023, $ Billion

The Business Research Company’s Global Vascular Grafts Market Report 2020-30: COVID-19 Growth And Change

LONDON, GREATER LONDON, UK, September 30, 2020 /EINPresswire.com/ — Companies in the vascular grafts market are increasingly investing in technological advances for the development of innovative vascular grafts, including customization of vascular grafts. For instance, RelayPro, a thoracic stent graft system recently launched by Terumo Aortic, is a low-profile device designed for patients with smaller access vessels in the treatment of thoracic endovascular aortic repair (TEVAR). It offers a broad range of diameters, lengths, tapers, and proximal configurations to the physicians. Both bare stent and non-bare stent (NBS) versions are available for this device and it can be customized to meet the patient’s specific anatomical needs.

The global vascular graft market size is expected to decline from $2.79 billion in 2019 to $2.6 billion in 2020 at a compound annual growth rate (CAGR) of -6.98%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The global vascular graft market size is then expected to recover and reach $3.27 billion in 2023 at a CAGR of 8.02%.

The rising prevalence of vascular diseases is driving the growth of the global vascular grafts market. According to a study by the National Center for Biotechnology Information in the US, cardiovascular diseases are the leading cause of death in the world, and according to the American Heart Association (AHA), in 2018, the overall prevalence of myocardial infarction in the US was around 7.9 million per year, while the estimated annual incidence of a heart attack in the US is 720,000 new attacks and 335,000 recurrent attacks. According to a study by NHS Inform, a national health service of Scotland, every year around 20,000 coronary bypass grafts are carried out in England. Therefore, the high prevalence of vascular diseases is anticipated to drive the global vascular grafts market.

The vascular graft global market share consists of sales of vascular grafts and related services by entities (organizations, sole traders and partnerships) that manufacture vascular grafts that are used to repair the diseased or blocked blood vessel during the surgical procedure called vascular grafting or vascular bypass. Vascular grafting is performed to bypass a partial or complete blockage in an artery by reconnecting the blood vessels. This process will improve the blood flow by redirecting blood from one area of the body to another. Vascular grafts are mainly used in the heart during coronary artery bypass and in legs to treat vascular disease.

Here Is A List Of Similar Reports By The Business Research Company:
Peripheral Vascular Devices And Equipment Global Market Report 2020-30: Covid 19 Impact And Recovery (https://www.thebusinessresearchcompany.com/report/peripheral-vascular-devices-and-equipment-global-market-report)

Cardiovascular Medical Lasers Global Market Report 2020-30: Covid 19 Growth And Change (https://www.thebusinessresearchcompany.com/report/cardiovascular-medical-lasers-global-market-report-2020-30-covid-19-growth-and-change)

Cardiovascular Surgery Devices And Equipment Global Market Report 2020-30: Covid 19 Impact And Recovery (https://www.thebusinessresearchcompany.com/report/cardiovascular-surgery-devices-and-equipment-global-market-report)

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire